(SI extract =110.7), Juglans australis (SI extract =8.1) and Lippia alba (SI extract =19.2) against BVDV-1, HSV-1 and influenza A virus, respectively, justify a further analysis. None of the seven plants assayed against HIV-1 displayed any antiviral activity. The results of this study justify the continuing isolation and characterization of the antiviral components present.
Viral infections have high mortality and morbidity rates worldwide, and increasing resistance to antiviral agents causes serious medical problems. The lack of effective therapies and/or vaccines for several viral infections and drug intolerance support the need for new antiviral drug development. A huge chemical diversity can be found amongst natural products, such as fungi, marine fauna and flora, bacteria and plants. Research on antiviral natural products is mainly focused on plants since, among other reasons, they can be selected on the basis of their ethnomedicinal use. In our laboratory we evaluate plants that have long been used by the aboriginal population of Argentina as a medicine against different diseases (Kott et al., 1999; García et al., 1999; Ruffa et al., 2002) . Exploring plants with ethnopharmacological backgrounds will lead to the detection of new compounds with relevant antiviral activity.
In this study, we investigated the antiviral activity of 15 selected Argentine medicinal plants. The selection of these species was based on their reputation as folk medicines in the treatment of viral diseases or possible symptoms of viral illnesses (Table 1) .
Viruses assayed herein were chosen for their different structural characteristics, replication mechanisms and pathogenesis: bovine viral diarrhoea virus type 1 (BVDV-1) and influenza virus type A, representing RNA viruses; herpes simplex virus (HSV) representing DNA viruses; and human immunodeficiency virus type 1 (HIV-1), representing retroviruses.
BVDV is a pestivirus within the Flaviridae and is used as an attractive model system to characterize the replication of the closely related hepacivirus, hepatitis C virus (HCV), a major cause of hepatitis and chronic liver disease and for which an infectious cell culture system does not exist (Thiel et al., 1996) .
Controlling influenza continues to be a major public health concern and much effort has been extended towards the discovery and development of antiviral drugs for treatment of this significant viral disease.
HSV is a ubiquitous agent that causes a variety of diseases ranging in severity from mild to severe. Nucleotide analogues such as acyclovir (ACV), penciclovir and others, are usually effective in treating primary or permanent HSV infections. However, the widespread use of nucleoside-based drugs, especially among immunocompromised patients, selects resistance. The high prevalence of HSVresistant strains among these populations suggests that new antiviral drugs should be discovered. 
Materials and methods

Plant material
Extraction procedure
Powdered leaves and stems (10 g) from each plant were extracted with 100 mL methanol (methanolic extracts: E). The extracts were taken to dryness at 40°C under vacuum. From each plant's ground material, 10 g were taken to make infusions (I) with 100 mL hot water and then lyophilized.
Sample preparation
Plant extracts were suspended (10 mg/mL) in dimethylsulphoxide/water (1:5) and the infusions in water. After centrifuging at 10000 g for 5 min, the supernatant was diluted in the corresponding medium.
Cells
Vero (African green monkey kidney ATCC CCL 1587), MDBK (Madin-Darby bovine kidney ATCC CRL 6071) and MDCK (Madin-Darby canine kidney ATCC CCL 34) cells were grown in Eagle's minimal essential medium (MEM) supplemented with 10% irradiated fetal bovine serum (FBS), glutamine 2 mM, sodium bicarbonate 2.25 g/L, non essential amino acids 1 mM and 100 units/mL of penicillin G sodium-100 µg/mL streptomycin sulphate (growth medium, GM).
Peripheral blood mononuclear cells (PBMC) were prepared and handled as previously described (Salomón et al., 1994) .
All cell lines were cultured at 37°C in a 5% CO 2 humidified atmosphere. 
Viruses assayed
Antiviral activity screening
Cytopathic effect (CPE) inhibitory assay. In a 96-well culture plate, 10-fold serial dilutions of the virus inoculum were seeded on Vero (HSV-1 and 2) and MDCK (influenza A) confluent and MDBK (BVDV-1) sub-confluent monolayers. Prior to the viral infection, the plate was seeded with different plant I or E concentrations, prepared in the corresponding infection medium (IM: GM without FBS and with trypsin 5 µg/mL for influenza A, 2% FBS for HSV or 5% donor horse serum for BVDV-1). Wells of mock infected and infected cells without samples served as cell and viral controls respectively. Cytotoxic controls were also added (mock-infected cells in the presence of E or I). The plates were incubated at 37°C in a 5% CO 2 humidified atmosphere for 72 h; monolayers were fixed and stained with a 0.3% crystal violet solution in 2% ethanol -3% formaline.
The samples that reduced 2 log of viral CPE at the maximum non-cytotoxic concentration (MNCC, determined by microscopic examination of morphology integrity after an 
Effective concentration 50% (EC 50 ) determination
The detection of anti-influenza A activity was tested by the MTT method (Mosmann, 1983) in which the MDCK viability (that correlates with the number of non-infected cells) was determined. The absorbances were read at 546 nm and 650 nm (background) and the inhibition percentage of virus-induced CPE was calucated as: The sample concentration that reduces the CPE by 50% in relation to the control value (EC 50 ) was determined from the inhibition graph of virus-induced CPE percentage versus E or I concentration (µg/mL) (Levi et al., 1995; Smee et al., 2002) .
To determine the EC 50 extract of the active extracts against BVDV-1, HSV-1 and HSV-2 the plaque reduction assay was utilized as mentioned above.
Plaque reduction assay. Confluent Vero (for HSV-1 and HSV-2) and sub-confluent MDBK (for BVDV-1) monolayers, cultured in 24-well plates, were infected with 100 plaque forming units (PFU)/well, in the presence of the various sample concentrations of E and I. The virus was removed after a 45 min adsorption period at 37°C (5% CO 2 ) and then the monolayers were washed and overlaid with plaque medium (PM: IM with methyl cellulose 0.5%) containing serial non-cytotoxic concentrations of E/I dilutions in triplicate. After 72 h, cells were fixed with 10% formaline and stained with 0.4% crystal violet. Plaques were counted and expressed as PFU/well. Viral, cellular and cytotoxic controls were performed in each assay.
Antiviral activity was determined as 50% effective concentration (EC 50 extract )-in other words, the E/I concentration required to reduce the viral PFU/well by 50% with respect to the control virus. It was determined from the graph displaying the plaque reduction rate in terms of sample concentration.
Anti-HIV screening. PBMC were activated with phytohaemaglutinin and then infected with HIV-1 at 37°C for 2 h. After infection, cells were washed and placed (4.5×10 5 cells/well) in a 96-well plate in the presence of different I or E concentrations. Wells treated with 3-azido-2′,3′-dideoxythymidine (AZT, Sigma) were included as a positive control of anti-HIV-1 effect. Cell-free supernatant fluids were harvested at day 7 and assayed for quantitive detection of the p24 HIV-1 antigen by an ELISA kit (Coulter HIV-1 p24 Antigen Assay, Beckman Coulter). The EC 50 was determined as the sample concentration reducing the p24 antigen production to half the value of the viral control (cells infected in the absence of the samples).
Cytotoxic assay
Cytotoxic concentration (CC 50 determination). Cytotoxicity studies were performed to determine the concentration of plant I or E that inhibits 50% of the cell viability (CC 50 extract ). Vero, MDBK, MDCK (3.5×10 3 cells/well) and PBMC (4.5×10 5 cells/well) cells in GM were seeded in 96-well plates and incubated in a humidified atmosphere at 37°C (5% CO 2 ) for 24 h. When the cells were in the growth exponential phase, double serial dilutions of the samples in GM was added in quadruplicate. The plates were further incubated for either 7 days (PBMC) or 3 days (the other cells). Cell viability was evaluated by the MTT (Sigma, Cat No M-5655) assay and the CC 50 extract was determined as the sample concentration that causes a 50% reduction in the number of viable cells as compared with the cellular control cells that were incubated with GM only (Freshney, 2000) .
Results
To determine the antiviral activity of 15 medicinal plants, a preliminary screening by the CPE inhibition assay was performed against BVDV-1, HSV-1, HSV-2 and influenza A. The samples which reduced 2 log of the viral CPE at the MNCC were considered active; their activity was confirmed by the plaque reduction assay (BVDV-1, HSV-1 and HSV-2) or MTT method (influenza).
The Selective Index (SI extract =CC 50 extract /EC 50 extract ), or the ratio between cytotoxic cell concentration 50% (CC 50 ) and the effective concentration 50% (EC 50 ), was calculated for all the active plant extracts. Extracts with SI values higher than eight contain potentially useful compounds (Hayashi et al., 1998) .
Among all the evaluated plants of this study, S. molle (E and I), Cor. didymus (E), M. ilicifolia (I), Phyllantus spp. (E), Er. japonica (I), N. glauca (E and I), Pa. debilis (E) and L. alba (E) were not active against the tested viruses.
H. bonariensis (I and E), Ce. pachystachya (E) and Cor. didymus (I), all active against BVDV-1 in the screening, presented high SI values, especially the Cor. didymus I (SI extract =110.7) ( Table 2) .
J. australis (E and I) and Er. japonica (E) were active against HSV-1 and 2, but only the infusion of J. australis The mean CC 50 and EC 50 were evaluated from three independent assays and the standard deviation was determined with a 95% confidence interval.
had an acceptable SI value against HSV-1 (SI extract =8.1)( (Table 2) .
Based on the ethnobotanical background, only seven of the 15 medicinal plants were tested against HIV-1. After viral infection in the presence of the samples, HIV-1 replication was evaluated by testing the p24 antigen production. None of the studied medicinal plants (J. australis, Ce. pachystachya, L. alba, N. glauca, Cor. didymus, H. bonariensis and Phyllantus spp.) was active.
Discussion
The aim of this work was to evaluate the antiviral activity of 15 Argentine medicinal plants against five clinically relevant viruses (BVDV-1, influenza A, HSV-1, HSV-2 and HIV-1). Plant species were selected based on their everyday use. They were collected in the Buenos Aires, Misiones and Tucumán, provinces of Argentina. Infusions and methanolic extracts were prepared and evaluated by the CPE inhibitory assay, plaque assay and reduction of the p24 HIV-1 antigen production.
BVDV-1 has a high rate of prevalence in cattle and causes significant economic loss worldwide; moreover, there are no effective antivirals against it. In addition, BVDV has received increasing attention as a surrogate model for the search of anti-HCV agents (Buckwold et al., 2003) . The determined SI extract from the three plants active against BVDV-1 are higher that eight; the infusion of Cor. didymus showed the highest SI value (SI=110.7). This is a species that has little reported biological activity and no described antiviral effect.
J. australis and Er. japonica inhibited HSV-1 and HSV-2. J. australis had a SI high enough to further analysis consideration. Previous studies reported a weak anti-HSV-1 and anti-HSV-2 activity of Er. japonica (Zheng, 1988; Minshi, 1989) . Other Juglans species such as J. regia and J. mandshurica have been reported active against herpes virus infections (Kaij-a- Kamb et al., 1992; Kurokawa et al., 1996) . This native species from Argentina is interesting because its popular uses (for ulcers, eczemas, rash, dermatitis and irritations) supports its efficacy in treating HSV infection. In consequence, studies are currently being carried out to isolate and characterize the compound/s responsible for the aforementioned activity.
Five of the 10 active plants against influenza A show a SI higher than eight. L. alba I is the most promising species, with a SI extract of 19.2. The most common use for the Lippia species is the treatment of respiratory disorders, (Pascual et al., 2001) . Further study of L. alba extract should be performed to evaluate its activity against strains of influenza viruses A and B, and other viruses which cause respiratory infections such as respiratory syncytial virus, rhinovirus and adenovirus.
None of the plant extracts assayed against HIV-1 was active.
The complex nature of plant extracts justifies a more detailed evaluation of Cor. didymus, J. australis and L. alba as a source of antiviral drugs against BVDV-1 (and probably anti-HCV), HSV and influenza A, respectively. The development of experimental strategies to isolate and characterize the pure bioactive principles will provide new potential antiviral agents to treat these relevant viral infections.
